去纤苷（defiteli）的适应症有什么？

What are the indications for defibrotide (defiteli)? Defibrotide (defiteli) is an important drug suitable for the treatment of hepatic veno-occlusive disease.

Defibrotide (defiteli) is a single-stranded oligonucleotide mixture that has anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defiteli (defiteli) is a safe and effective drug for preventing and treating HVOD after HSCT. Defiteli (defiteli) was first developed by Gentium Pharmaceuticals in Italy and was approved for marketing in the EU in October 2013. After Gentium Pharmaceuticals was acquired by Jazz Pharmaceuticals of the United States, defiteli (defiteli) was approved by the US Food and Drug Administration (FDA) to be launched in the United States on March 30, 2016, under the trade name Defitelio. 

Defibrotide (defiteli) is a mixture of single-stranded oligonucleotides broken down from genomic DNA from calf lung or porcine intestinal mucosa. The oligonucleotide chain length of DF varies, the relative molecular mass ranges from 15×10³-30×10³, and its purine to pyrimidine ratio is greater than 0.85. The mechanism of action of defiteli is complex and is not yet fully understood. Preclinical trials have confirmed that defiteli has anti-thrombotic, fibrinolysis, anti-ischemic, and anti-infective effects in vivo and in vitro. The recommended dose of defiteli for adult and pediatric patients is 6.25 mg/kg every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Give defibrotide (defiteli) for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days. Do not coadminister defibrotide (defiteli) with other intravenous medications at the same time and in the same intravenous line.

The above is the introduction provided by our Medical Companion Overseas Medical Consulting Service Company about the indications of defiteli (defiteli): hepatic veno-occlusive disease.